SGLT2 inhibitors for diabetes are linked to increased risk of lower limb amputationBMJ 2018; 363 doi: https://doi.org/10.1136/bmj.k4828 (Published 14 November 2018) Cite this as: BMJ 2018;363:k4828
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events
- Zosia Kmietowicz
- The BMJ
Patients with type 2 diabetes treated with sodium glucose cotransporter 2 (SGLT2) inhibitors have a higher risk of lower limb amputation and diabetic ketoacidosis than those who take glucagon-like peptide 1 (GLP1) receptor agonists, a study published in The BMJ has found.1
SGLT2 inhibitors are increasingly used in treating type 2 diabetes. But some studies suggest that they are associated with serious complications, including lower limb amputation, bone fracture, diabetic ketoacidosis, acute kidney injury, serious urinary tract infections, venous thromboembolism, and acute pancreatitis.
To better understand these …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.